Want to see EHTH full AI Analyst Report?
Top Page
Ehealth
(NASDAQ:EHTH)
Select Model
Select Model
Rating:51Neutral
Price Target:
$1.50
▲(10.29% Upside)
Action:Reiterated
Date:08/05/26
The score is held back primarily by persistent negative operating/free cash flow and weakening TTM profitability/revenue trends despite the earlier turnaround. Technicals also remain bearish with the stock below major moving averages and a negative MACD. The latest earnings call provides partial offset via maintained guidance, cost reductions, and a stated roadmap to improved operating cash flow, but near-term revenue and gross profit headwinds remain significant.
Positive Factors
Liquidity and Receivables Strength
Substantial cash plus a large, growing commission receivables balance gives the company runway to execute restructuring and marketing cadence changes. Durable receivables underpin future commission realization and provide cushion versus short-term revenue volatility while the business reorients.
Negative Factors
Persistent Negative Operating and Free Cash Flow
Repeated negative operating and free cash flow despite episodic GAAP profitability shows weak cash conversion. This creates ongoing reliance on balance-sheet liquidity and receivables monetization; if cash conversion does not sustainably improve, financial flexibility and reinvestment capacity remain constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
Liquidity and Receivables Strength
Substantial cash plus a large, growing commission receivables balance gives the company runway to execute restructuring and marketing cadence changes. Durable receivables underpin future commission realization and provide cushion versus short-term revenue volatility while the business reorients.
Read all positive factors
Ehealth (EHTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.76M
Dividend YieldN/A
Average Volume (3M)410.85K
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue Growth-8.37%
EPS Growth-220.33%
CountryUS
Employees1,665
SectorFinancial
Sector Strength70
IndustryInsurance - Brokers
Share Statistics
EPS (TTM)-0.83
Shares Outstanding32,032,654
10 Day Avg. Volume210,710
30 Day Avg. Volume410,845
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.14
Price to Sales (P/S)0.25
P/FCF Ratio-3.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.88Price Target Upside37.87% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.57
Revenue Forecast (FY)$429.27M
Ehealth Business Overview & Revenue Model
Company Description
eHealth, Inc. operates a digital health insurance marketplace within the United States, dedicated to engaging consumers, educating them, and simplifying the health insurance enrollment process. Its operations are categorized into two main division...
How the Company Makes Money
eHealth primarily earns revenue by acting as an insurance broker and receiving commissions from insurance carriers for policies it facilitates. The main revenue stream is carrier commissions associated with Medicare-related enrollments (notably Me...
Ehealth Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Neutral
The call presented a balanced mix of strong operational progress and short-term financial headwinds. Positive developments include the launch of the lifetime advisory model with encouraging early cross-sell results, meaningful cost reductions, substantial quarterly cash flow improvement, AI-driven efficiency gains, and maintained guidance with a roadmap to return to growth in 2027. Offsetting these positives are steep year-over-year declines in Q2 revenue (down 45%), compressed Medicare gross profit (down ~68.6%), deeper GAAP and adjusted EBITDA losses, lower tail revenue, and higher per-member customer care costs. Management expects additional near-term revenue headwinds due to planned marketing reductions before re-allocating spend into Q4. Overall, the call signals progress on restructuring and cash-flow improvement but continued short-term operational and revenue challenges.Positive Updates
Launch of Lifetime Advisory Model and Early Validation
Company launched lifetime advisory model in Q2; advisers trained and new tools deployed. Early validation: ancillary cross-sell rates doubled year-over-year in Q2 (100% increase), and final expense product launched in Q2. Management expects improved retention, broader member LTV metrics, and increased cross-selling as the model matures.
Negative Updates
Sharp Revenue Decline in Q2
Second-quarter total revenue was $33.6 million, down 45% year-over-year. Medicare segment revenue was $31.8 million, also down 45%. Medicare submissions declined 44% and non-commission revenue fell 38% year-over-year.
Read all updates
Q2-2026 Updates
Positive
Negative
Launch of Lifetime Advisory Model and Early Validation
Company launched lifetime advisory model in Q2; advisers trained and new tools deployed. Early validation: ancillary cross-sell rates doubled year-over-year in Q2 (100% increase), and final expense product launched in Q2. Management expects improved retention, broader member LTV metrics, and increased cross-selling as the model matures.
Read all positive updates
Company Guidance
Management said it is maintaining its 2026 guidance ranges for revenue, GAAP net income, adjusted EBITDA and operating cash flow while updating 2026 net adjustment (tail) revenue to $16–$20 million, and reiterated a goal of break‑even or better operating cash flow at the midpoint of guidance (with year‑over‑year operating cash flow improvement expected in each remaining quarter and positive operating cash flow targeted in 2027). They forecast annual variable cost savings of >$60 million and fixed cost savings of ~$30 million, will cut Q3 marketing spend even more than the 45% y/y reduction in Q2 and deploy the bulk of marketing in Q4, and expect ICHRA revenue to remain below $5 million in 2026. Liquidity and operating datapoints cited included $101 million of cash and short‑term marketable securities, $1.0 billion of commission receivables (+10% y/y), cumulative tail revenue of $284 million since 2018, and Q2 results of $33.6 million revenue, GAAP net loss $23.6 million, adjusted EBITDA loss $21.8 million and Q2 operating cash flow of negative $5 million.Ehealth Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
66
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 501.69M | 554.01M | 532.41M | 452.87M | 405.36M | 538.20M |
| Gross Profit | 491.93M | 540.25M | 530.62M | 451.10M | 403.71M | 536.21M |
| EBITDA | 67.36M | 83.25M | 46.81M | 295.00K | -77.65M | -105.18M |
| Net Income | 27.18M | 40.04M | 10.06M | -28.21M | -88.72M | -104.38M |
Balance Sheet | ||||||
| Total Assets | 1.16B | 1.26B | 1.16B | 1.11B | 1.11B | 1.15B |
| Cash, Cash Equivalents and Short-Term Investments | 101.05M | 77.22M | 82.24M | 121.65M | 144.40M | 123.23M |
| Total Debt | 132.17M | 134.35M | 96.92M | 103.16M | 106.80M | 41.37M |
| Total Liabilities | 617.23M | 288.82M | 567.00M | 209.26M | 461.66M | 399.77M |
| Stockholders Equity | 540.80M | 973.65M | 588.43M | 904.08M | 650.96M | 749.52M |
Cash Flow | ||||||
| Free Cash Flow | -1.40M | -40.65M | -31.22M | -17.47M | -42.38M | -183.48M |
| Operating Cash Flow | 5.31M | -25.34M | -18.37M | -6.69M | -26.87M | -162.62M |
| Investing Cash Flow | -36.71M | 25.43M | -48.42M | -15.89M | 25.86M | -12.63M |
| Financing Cash Flow | 35.48M | 34.29M | -9.32M | -6.22M | 63.84M | 213.24M |
Ehealth Technical Analysis
Negative
1.36
Price Trends
1.51
Negative
1.58
Negative
2.41
Negative
Market Momentum
-0.08
Positive
38.06
Neutral
7.91
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EHTH, the sentiment is Negative. The current price of 1.36 is above the 20-day moving average (MA) of 1.33, below the 50-day MA of 1.51, and below the 200-day MA of 2.41, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 38.06 is Neutral, neither overbought nor oversold. The STOCH value of 7.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EHTH.
Ehealth Risk Analysis
Ehealth disclosed 41 risk factors in its most recent earnings report. Ehealth reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ehealth Peers Comparison
UnderperformOutperform
Sector (68)
EHTH
Ehealth
1.22
-2.34
-65.73%
HUIZ
Huize Holding
1.24
-1.26
-50.40%
SLQT
SelectQuote
0.73
-1.27
-63.60%
Ehealth Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
eHealth Shareholders Expand Equity Plan and Elect Directors
Positive
Jun 25, 2026
At its annual meeting on June 18, 2026, eHealth, Inc. shareholders approved an amendment and restatement of the company’s 2024 Equity Incentive Plan, increasing the maximum number of shares that may be issued under the plan by 1,300,000, a m...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresShareholder Meetings
eHealth Posts Q1 Results Amid Strategic Shift, Maintains Outlook
Neutral
May 6, 2026
On May 3, 2026, eHealth director Cesar Soriano informed the board he will resign from the board and its committees immediately before the company’s June 18, 2026 annual meeting, citing the growing demands of his role as CEO of Confie Corpora...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.